Grifols (GRFS) said Tuesday it received an expanded indication from the US Food and Drug Administration for the Thrombate III concentrate to add pediatric patients diagnosed with hereditary antithrombin deficiency, a blood clotting disorder.

Thrombate III is now the first and only antithrombin concentrate approved for adults and pediatrics with hereditary antithrombin deficiency, according to the company.